• Nymox Pharmaceutical Corp., of Hasbrouck Heights, N.J., said an analysis of results from its new multicenter Phase II study of NX-1207 for benign prostatic hyperplasia (BPH) showed statistically significant superiority to finasteride, an approved treatment. In the intent-to-treat cohort in the study after 90 days, the tested therapeutic dose of NX-1207 had a mean BPH Symptom Score improvement of 9.71 points, compared to improvement of 4.13 points shown by finasteride. The difference was statistically significant (p=0.001). There were no significant side effects from NX-1207 in the trial. Full results from the study will be released at peer-review medical meetings later in 2008.

• Thallion Pharmaceuticals Inc., of Montreal, has completed patient enrollment for the Phase II trial of CAP-232 in refractory renal cell carcinoma patients. The open-label trial is designed to assess the safety and pharmacokinetic profile of Thallion's new continuous intravenous formulation of CAP-232, as well as provide efficacy data in patients who had failed to benefit from the current standard of care. The trial will administer 0.48 mg/kg/day of CAP-232 through continuous intravenous infusion for three cycles, each cycle consisting of 21 days of treatment followed by seven days of rest.